Annexon Completes Enrollment In Phase 3 ARCHER II Trial, On Track To Report Data In 2H 2026

Annexon (ANNX) has completed enrollment for its Phase III ARCHER II trial of Vonaprument, a candidate treatment for dry age-related macular degeneration with geographic atrophy, having enrolled over 630 patients. This key clinical milestone, following positive Phase II results, positions the company to report topline data in the second half of 2026. If successful, Vonaprument could become the first approved treatment in Europe and the U.S. for this condition based on visual acuity and structural measures, representing a significant market opportunity for Annexon in an area of high unmet medical need.

Analysis

Annexon Inc. has achieved a significant operational milestone by completing enrollment for its Phase III ARCHER II trial, a pivotal study for its drug candidate Vonaprument in treating dry age-related macular degeneration with geographic atrophy. Surpassing the enrollment target of 630 patients ahead of schedule signals strong clinical site execution and high patient/physician interest, which can be a positive leading indicator for trial progression. The drug's potential is underscored by a successful Phase II study that demonstrated vision preservation, and the Phase III trial's primary endpoint—preventing a loss of 15 or more letters in BCVA—is a well-established, clinically meaningful measure. A successful outcome could position Vonaprument as a first-in-class therapy in the U.S. and Europe based on protecting visual acuity, a potentially major commercial advantage. However, the key catalyst, the topline data readout, is not expected until the second half of 2026. This extended timeline positions ANNX as a long-term, event-driven investment, with its current stock price of $2.48 trading at the lower end of its 52-week range of $1.28 to $7.85, suggesting the market is awaiting definitive data before fully pricing in the potential success.

Key Decisions for Investors

• Investors with a long-term horizon and high risk tolerance might consider the current valuation an opportunity, as the successful trial enrollment de-risks the operational timeline for a major catalyst in H2 2026.
• Given the binary nature of Phase III trial outcomes in biotech, positions in ANNX should be sized appropriately to account for the significant downside risk of trial failure.
• Traders and investors should monitor for any interim updates from the trial and keep a close watch on competitive developments within the geographic atrophy space, as these could materially impact Vonaprument's market potential ahead of the 2026 data release.